Vitamin D has obtained far-flung attention as a plausible player in preventing cardiovascular disease, cancer and type 2 diabetes mellitus. Supplemental vitamin D is presently incorporated to prevent and treat bone related disorders, but interest has been rising in its application for preventing cancer and cardiovascular disease. This is mainly based on some previous epidemiological studies that suggested people with low blood levels of vitamin D developed increased risks of stroke, hypertension, heart disease, and diabetes in regions with greater sun exposure. Yet JoAnn E. Manson explains how it is scientifically not possible for such a large body to have such major influence with the recommended high intakes of vitamin D and why the previous research was found to be inadequate for prevention of cardio metabolic outcomes with Vitamin D.
Realizing the in-depth probing on the topic, and taking commendation by Institute of Medicine (IOM) of inconsistent and inconclusive potential of vitamin D as a preventive measure for cancer and other nonskeletal outcomes, the need for future research got initiated by Manson.
Taking the implication into consideration, researchers Mason working on the CRUCIAL clinical trial scrutinized if high-dose vitamin D supplements provide protection against cancer or cardiovascular disease. A massive trial undertaking a total of Nearly 26,000 (25,871) participants, including one-fifth (5,106) of black participants, particularly men aged 50 years or older and women 55 years or older were randomized. In this large randomized primary-prevention trial, researcher JoAnn E. Manson, M.D in association with co-authors evaluated whether supplementation with vitamin D minimizes the menace of cancer (besides nonmelanoma skin cancer) or cardiovascular disease among. The author included a number of black populations mainly for a reason as because this population does not absorb vitamin D from the sun as well as other demographics. Randomly appointing each participant of the study to supplementation or to placebo, the investigators observed Vitamin D supplementation to play an inconsequential role in lowering risk of either of the primary endpoints. Moreover at follow-up a mean 5.3 years later, cancer was diagnosed among 1,617 participants as well as a major cardiovascular event in 805 study participants.
Further, on comparison with placebo, supplementation with vitamin D3 made no move in significantly lowering episodes of invasive cancer of any kind or a conglomeration of considerable cardiovascular events (stroke, myocardial infarction, and death from cardiovascular inductions). Moreover, the intervention not showed to activate diminished incidence of total deaths from cancer or a downsizing in incidence of prostate, breast, or placebo vs. colorectal cancer. The investigator confirmed cancer diagnosis in 793 participants in the vitamin D group and in 824 in the control group at a median follow-up of 5.3 years. Correspondingly, a major cardiovascular event affected 396 supplement-takers and 409 placebo-takers.
Based on the outcomes, the researcher JoAnn E. Manson concluded that consuming vitamin D supplements does not help lowering the risk of invasive cancer or cardiovascular events any more than placebo.
The author finds the treatment to have not medically met the criteria in establishing a cause and effect relationship, which is also consistent with previous trials conducted by the Agency for Healthcare Research and Quality (AHRQ) that hinted vitamin D may fall short in preventing cancer and heart disease. However those clinical trials were smaller and used smaller doses of vitamin D and most were formulated to examine the effects of the supplement on other health problems, such as bone strength. But vitamin D did not seem to help bone health either and found no evidence that it could reduce falls or fractures and found limited benefit for bone density.
Manson’s research also undertook whether consuming a fish oil supplement in a preparation similar to what users can get OTC affects heart health and cancer threat. As with vitamin D in primary prevention, the author found no noticeable difference between those taking a daily 1-gram capsule containing omega-3 fatty acids and those taking a placebo. The author further commended that low vitamin D in the blood might just be a marker of an individual in a poorer health in general.
That said, despite biological incompetency for a role of vitamin D as to cancer and cardiovascular causality, the author found no risks of hypercalcemia or other adverse events from available researches.